Condition: Advanced or Metastatic Solid Tumors · Sponsor: Kyowa Kirin Co., Ltd.
This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). In Part 1b and Part 2, at least two dosing regimens and two dosing regimens by cancer type, respectively, will be selected, and the safety, tolerability, and efficacy of each regimen will be evaluated.
This description comes directly from the study's public registry record.
Kyowa Kirin Co., Ltd. · +81-3-5205-7200 · clinical.info.jp@kyowakirin.com
Always discuss trial participation with your own doctor first.
| Aichi Cancer Center Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| Shikoku Cancer Center | Matsuyama, Ehime, Japan | Recruiting |
| Hiroshima University Hospital | Hiroshima, Hiroshima, Japan | Recruiting |
| Kobe University Hospital | Kobe, Hyōgo, Japan | Recruiting |
| Kanagawa Cancer Center | Yokohama, Kanagawa, Japan | Recruiting |
| Kumamoto University Hospital | Kumamoto, Kumamoto, Japan | Recruiting |
| Tohoku University Hospital | Sendai, Miyagi, Japan | Recruiting |
| Saitama Cancer Center | Shinden, Saitama, Japan | Recruiting |
| Shizuoka Cancer Center | Nagaizumi-cho, Shizuoka, Japan | Recruiting |
| National Cancer Center Hospital | Chuo-ku, Tokyo, Japan | Recruiting |
| The Cancer Institute Hospital of JFCR | Koto-ku, Tokyo, Japan | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06248411